News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
3 hrs ago | Modern Healthcare
Baxter International is selling its vaccine business to Pfizer for $635 million as it prepares to split into two companies.
9 hrs ago | The Washington Post
AstraZeneca Plc raised its forecast after reporting quarterly profit that beat analyst estimates, helped by a $200 million payment from one-time suitor Pfizer Inc. for rights to an over-the-counter version of the Nexium heartburn treatment.
Pfizer reported second-quarter results which were more or less in line with consensus estimates.
In bygone centuries, medicine consisted of bloodletting and leeches. Cures were simple and inexpensive, if petrifying.
Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania.
The acquisition grants Pfizer access to Baxter's meningitis vaccine, NeisVac-C, and encephalitis vaccine, FSME-IMMUN, along with a part of Baxter's Austrian facility that produces the drugs.
Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.
Merck & Co., the second-biggest U.S. drugmaker, is staying in the United States and sticking to a bolt-on acquisition strategy, shunning the route taken by its biggest rival, Pfizer Inc. Merck, maker of the diabetes pill Januvia, is not interested in large-scale purchases that are "very time-consuming and distracting to what we're here to do, which ... (more)
Good day, everyone and welcome to Pfizer's Second Quarter 2014 Earnings Conference Call.
Failing to buy AstraZeneca Plc with the drug industry's largest-ever deal hasn't stopped Pfizer Inc.'s Ian Read from looking far and wide for acquisitions.
Ranjith Gopinathan, who is a program manager, life sciences and healthcare practice at Frost & Sullivan during an interview on CNBC said that while Merck & Co., Inc. has to go for some kind of acquisition to strengthen its pipeline and because of that, I think, Pfizer Inc. in May, when the latter turned down its $118 billion bid offer.
Acclerator Corp., a Seattle a life-science investment firm that focuses on biotech businesses, said it's raised $51.1 million in capital funding, and will expand to New York City.
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Helping reverse a nationwide trend of fewer female venture capitalists in recent years, Polaris Partners has named the only female partner currently at any of the area's top VC firms.
United Parcel Service driver Marty Thompson starts his truck up after making a delivery in Cumming, Ga.
Polaris Partners , which is in the market for a $400 million seventh fund, has brought on board a noted healthcare general counsel.
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.
Updated: Thu Jul 31, 2014 10:56 am
Copyright © 2014 Topix LLC